TCTR20221222001Unknown不适用
Real-World Effectiveness and Safety of Dabigatran in Geriatric Patients with Atrial Fibrillation
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 2,134
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20 Years 至 100 Years（—）
- 性别
- All
入选标准
- •Thai patient who was more than twenty years old and got dabigatran 150 milligrams, 110 milligrams or 75 milligrams twice daily for non-valvular atrial fibrillation indication.
排除标准
- •- Patient with mechanical valve replacement or moderate to severe mitral stenosis.
- •- ESRD patient or eGFR less than 15 ml/min.
- •- Pregnancy or lactation patient.
- •- Incomplete patient data.
研究者
相似试验
招募中
3 期
efficacy and safety of dabigatran(paradxa) in pediatric thromboembolism Referring to Amir Kabir Hospital in Arakchildren-thromboemboli.Embolism and thrombosis of other arteriesIRCT20180711040431N1Arak University of Medical Sciences20
招募中
不适用
Evaluation of efficacy and safety of Dabigaran in patients with catheter ablation for atrial fibrillation.Atrial fibrillationJPRN-UMIN000011223Osaka City University Graduate School of Medicine140
招募中
不适用
Effect of Dabigatran (drug) in liver cirrhosis (liver disease)CTRI/2020/06/025846Institute of Liver and Biliary Sciences
进行中（未招募）
1 期
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of age.Venous Thrombotic EventMedDRA version: 14.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 10047065 - Vascular disordersEUCTR2009-013618-29-ESBoehringer Ingelheim España, S.A.18
进行中（未招募）
不适用
Safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of ageEUCTR2009-013618-29-ITBOEHRINGER ING.16